You can buy or sell Sophiris Bio and other stocks, options, ETFs, and crypto commission-free!
Sophiris Bio, Inc. Common Stock, also called Sophiris Bio, is a clinical-stage biopharmaceutical company, which engages in the development of products for the treatment of urological diseases. Read More The firm develops PRX302 as a treatment for the symptoms of benign prostatic hyperplasia which is a non cancerous enlargement of the prostate gland that causes a restriction in urine flow from the urethra resulting in lower urinary tract symptoms. The company was founded by James L. Heppell in May 2003 and is headquartered in La Jolla, CA.
La Jolla, California
52 Week High
52 Week Low
PR NewswireMar 13
Sophiris Bio Reports Fourth Quarter 2018 and Year-end Financial Results and Recent Corporate Highlights
SAN DIEGO and VANCOUVER, British Columbia, March 13, 2019 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company," "We" or "Sophiris"), a biopharmaceutical company developing topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today reported financial results for the fourth quarter and full year 2018 and recent corporate highlights. "During the past year, Sophiris has made important progress in determinin...
Simply Wall StFeb 26
Some Sophiris Bio Shareholders Have Copped A Big 65% Share Price Drop
We think intelligent long term investing is the way to go. But unfortunately, some companies simply don’t succeed. For example, after five long years the Sophiris Bio, Inc. (FRA:BFF1) share price is a whole 65% lower. That is extremely sub-optimal, to say the least. We also note that the stock has performed poorly over the last year, with the share price down 44%. Furthermore, it’s down 42% in about a quarter, which is even more concerning. View our latest analysis for Sophiris Bio Sophiris Bio didn’t hav...
-$0.12 per share
-$0.10 per share